(CLEM) Clemondo (publ) - Ratings and Ratios
Personal Care, Detergents, Cleaning, Hygiene, Beauty
CLEM EPS (Earnings per Share)
CLEM Revenue
Description: CLEM Clemondo (publ)
Clemondo Group AB is a Swedish personal care products company with a market capitalization of 148.16M SEK. The companys stock has a relatively low beta of 0.177, indicating low volatility compared to the overall market. With a forward P/E ratio of 10.21, the market expects earnings growth, potentially driven by the increasing demand for personal care products.
The companys return on equity (RoE) stands at 7.17%, which is a moderate value. To improve this metric, Clemondo Group AB could focus on optimizing its product portfolio, enhancing operational efficiency, and expanding its customer base. Key drivers for the personal care products industry include consumer spending habits, demographic changes, and trends in wellness and sustainability.
To evaluate Clemondo Group ABs performance, relevant KPIs could include revenue growth, gross margin, and sales per product category. The companys ability to innovate and adapt to changing consumer preferences will be crucial in maintaining its competitive edge. By analyzing these metrics and staying attuned to industry trends, investors can make informed decisions about the stocks potential.
From a valuation perspective, the stocks current price is near its 50-day simple moving average (SMA50) of 10.00 SEK, and above its 200-day simple moving average (SMA200) of 8.54 SEK, indicating a potential uptrend. The average trading volume of 15,041 shares suggests moderate liquidity, allowing investors to enter or exit positions relatively easily.
CLEM Stock Overview
| Market Cap in USD | 15m |
| Sub-Industry | Personal Care Products |
| IPO / Inception |
CLEM Stock Ratings
| Growth Rating | -19.0% |
| Fundamental | 58.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -4.30% |
| Analyst Rating | - |
CLEM Dividends
Currently no dividends paidCLEM Growth Ratios
| Growth Correlation 3m | -14% |
| Growth Correlation 12m | 61.8% |
| Growth Correlation 5y | -75.7% |
| CAGR 5y | -20.11% |
| CAGR/Max DD 5y | -0.24 |
| Sharpe Ratio 12m | -0.10 |
| Alpha | 7.10 |
| Beta | 0.300 |
| Volatility | 39.44% |
| Current Volume | 65.5k |
| Average Volume 20d | 20.2k |
| Stop Loss | 9.8 (-6.7%) |
| Signal | 2.18 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (8.21m TTM) > 0 and > 6% of Revenue (6% = 16.2m TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA -13.87pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 9.85% (prev 8.36%; Δ 1.49pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 15.8m > Net Income 8.21m (YES >=105%, WARN >=100%) |
| Net Debt (54.9m) to EBITDA (26.2m) ratio: 2.09 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.42 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (13.8m) change vs 12m ago 0.00% (target <= -2.0% for YES) |
| Gross Margin 37.82% (prev 19.82%; Δ 18.00pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 131.2% (prev 140.9%; Δ -9.66pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.20 (EBITDA TTM 26.2m / Interest Expense TTM 1.63m) >= 6 (WARN >= 3) |
Altman Z'' 1.45
| (A) 0.12 = (Total Current Assets 90.1m - Total Current Liabilities 63.5m) / Total Assets 221.6m |
| (B) 0.03 = Retained Earnings (Balance) 5.81m / Total Assets 221.6m |
| (C) 0.06 = EBIT TTM 11.7m / Avg Total Assets 205.7m |
| (D) 0.19 = Book Value of Equity 19.7m / Total Liabilities 105.2m |
| Total Rating: 1.45 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 58.56
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 2.33% = 1.16 |
| 3. FCF Margin 1.71% = 0.43 |
| 4. Debt/Equity 0.51 = 2.37 |
| 5. Debt/Ebitda 2.29 = -0.56 |
| 6. ROIC - WACC 2.23% = 2.78 |
| 7. RoE 7.17% = 0.60 |
| 8. Rev. Trend -26.44% = -1.32 |
| 9. Rev. CAGR -0.40% = -0.07 |
| 10. EPS Trend 46.44% = 1.16 |
| 11. EPS CAGR 141.6% = 2.50 |
What is the price of CLEM shares?
Over the past week, the price has changed by +6.60%, over one month by +0.00%, over three months by -2.78% and over the past year by +11.94%.
Is Clemondo (publ) a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CLEM is around 8.67 SEK . This means that CLEM is currently overvalued and has a potential downside of -17.43%.
Is CLEM a buy, sell or hold?
What are the forecasts/targets for the CLEM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 15 | 42.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 9.4 | -10.7% |
CLEM Fundamental Data Overview
Market Cap SEK = 138.5m (138.5m SEK * 1.0 SEK.SEK)
CCE Cash And Equivalents = 0.0 SEK (Cash only, last quarter)
P/E Trailing = 16.6667
P/E Forward = 10.2145
P/S = 0.513
P/B = 1.1899
Beta = 0.113
Revenue TTM = 269.9m SEK
EBIT TTM = 11.7m SEK
EBITDA TTM = 26.2m SEK
Long Term Debt = 41.7m SEK (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 18.2m SEK (from shortTermDebt, last quarter)
Debt = 59.9m SEK (Calculated: Short Term 18.2m + Long Term 41.7m)
Net Debt = 54.9m SEK (from netDebt column, last quarter)
Enterprise Value = 198.3m SEK (138.5m + Debt 59.9m - CCE 0.0)
Interest Coverage Ratio = 7.20 (Ebit TTM 11.7m / Interest Expense TTM 1.63m)
FCF Yield = 2.33% (FCF TTM 4.62m / Enterprise Value 198.3m)
FCF Margin = 1.71% (FCF TTM 4.62m / Revenue TTM 269.9m)
Net Margin = 3.04% (Net Income TTM 8.21m / Revenue TTM 269.9m)
Gross Margin = 37.82% ((Revenue TTM 269.9m - Cost of Revenue TTM 167.8m) / Revenue TTM)
Tobins Q-Ratio = 10.09 (Enterprise Value 198.3m / Book Value Of Equity 19.7m)
Interest Expense / Debt = 0.57% (Interest Expense 340.0k / Debt 59.9m)
Taxrate = 24.40% (from yearly Income Tax Expense: 1.99m / 8.16m)
NOPAT = 8.85m (EBIT 11.7m * (1 - 24.40%))
Current Ratio = 1.42 (Total Current Assets 90.1m / Total Current Liabilities 63.5m)
Debt / Equity = 0.51 (Debt 59.9m / last Quarter total Stockholder Equity 116.4m)
Debt / EBITDA = 2.29 (Net Debt 54.9m / EBITDA 26.2m)
Debt / FCF = 12.98 (Debt 59.9m / FCF TTM 4.62m)
Total Stockholder Equity = 114.5m (last 4 quarters mean)
RoA = 3.70% (Net Income 8.21m, Total Assets 221.6m )
RoE = 7.17% (Net Income TTM 8.21m / Total Stockholder Equity 114.5m)
RoCE = 7.49% (Ebit 11.7m / (Equity 114.5m + L.T.Debt 41.7m))
RoIC = 7.33% (NOPAT 8.85m / Invested Capital 120.8m)
WACC = 5.10% (E(138.5m)/V(198.3m) * Re(7.12%)) + (D(59.9m)/V(198.3m) * Rd(0.57%) * (1-Tc(0.24)))
Shares Correlation 5-Years: 35.90 | Cagr: 6.51%
Discount Rate = 7.12% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈14.9m ; Y1≈9.77m ; Y5≈4.47m
Fair Price DCF = 6.34 (DCF Value 87.8m / Shares Outstanding 13.8m; 5y FCF grow -40.0% → 3.0% )
Revenue Correlation: -26.44 | Revenue CAGR: -0.40%
Rev Growth-of-Growth: 9.77
EPS Correlation: 46.44 | EPS CAGR: 141.6%
EPS Growth-of-Growth: -64.23